# Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC

> **NCT05992584** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital of Guangzhou Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Lenvatinib, sintilimab plus SIRT

## Key facts

- **NCT ID:** NCT05992584
- **Lead sponsor:** Second Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-10
- **Primary completion:** 2026-01-09
- **Final completion:** 2026-08-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05992584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05992584, "Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05992584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*